Dyadic International, Inc.

169 articles with Dyadic International, Inc.

• Dyadic Announces Third Quarter 2020 Financial Results and Highlights Recent Company Progress

  11/12/2020

  Dyadic International, Inc., a global biotechnology company focused on further improving and applying its proprietary C1 gene expression platform to accelerate development, lower production costs and improve the performance of biologic vaccines and drugs at flexible commercial scales, announced its financial results for the quarter ended September 30, 2020, and recent developments.

• Dyadic to Report Third Quarter 2020 Financial Results on Thursday, November 12, 2020

  10/29/2020

  Dyadic International, Inc. announced that it will report its financial results for quarter ended September 30, 2020 after the market close on Thursday, November 12, 2020 and it will host a conference call that day at 5:00 p.m.

• Dyadic Updates Market on COVID-19 Initiatives

  10/12/2020

  Dyadic International, Inc., a global biotechnology company focused on further applying its proprietary C1 gene expression platform to accelerate development, lower production costs and improve the performance of biologic vaccines and drugs at flexible commercial scales, is updating the market on the progress made in certain of its coronavirus programs globally.

• Dyadic Announces Collaboration with Jiangsu Hengrui Medicine for Biologic Drug Development

  9/17/2020

  Dyadic International, Inc. today announced collaboration with Jiangsu Hengrui Medicine Co., Ltd. ("Hengrui") (SSE:600276) to apply Dyadic's C1 technology to the development of selected Hengrui biologic drug(s).

• Dyadic to Present at Upcoming Investor and Industry Events

  9/14/2020

  Dyadic International, Inc. today announced that the Company's management will be attending and presenting at the following investor and industry events in September:

• Dyadic Announces Second Quarter 2020 Results and Highlights Recent Company Progress

  8/13/2020

  Entered into two new collaborations with top tier animal health companies Entered into a fully funded human health collaboration with a top five global pharmaceutical company Started an animal trial for SARS-CoV-2 RBD vaccine candidate in Israel and another animal trial in European is expected to begin soon

• Dyadic to Report Second Quarter 2020 Financial Results on Thursday, August 13, 2020

  7/30/2020

  Dyadic International, Inc. today announced that it will report its financial results for quarter ended June 30, 2020 after the market close on Thursday, August 13, 2020

• Dyadic International Announces Fully Funded Human Health R&D Collaboration with a Top Five Pharmaceutical Company

  7/15/2020

  Dyadic International Announces Fully Funded Human Health R&D Collaboration with a Top Five Pharmaceutical Company today announced that it has entered into a new, fully-funded collaboration with another top five global pharmaceutical company.

• Dyadic Announces Two New Fully Funded Collaborations with Leading Global Animal Health Companies

  7/8/2020

  Dyadic Now Partnered with all of the Top Four Animal Health Companies Five Fully Funded Animal Health Research Projects with Three New Relationships Announced this Year

• Dyadic and Frederick National Laboratory to Develop Cell Lines for COVID-19 Vaccine Candidates Using Dyadic's C1 Gene Expression Platform

  6/15/2020

  Dyadic International, Inc. ("Dyadic" or the "Company") (NASDAQ:DYAI), today announced that it was selected by the Frederick National Laboratory to engineer its patented and proprietary C1 cell lines to produce a number of COVID-19 vaccine candidates

• Dyadic Reports 2020 First Quarter Results and Recent Developments

  5/18/2020

  Dyadic International, Inc., a global biotechnology company focused on further improving and applying its proprietary C1 gene expression platform to accelerate development, lower production costs and improve the performance of biologic vaccines and drugs at flexible commercial scales, announced its financial results for the quarter ended March 31, 2020, and recent developments.

• Dyadic International to Webcast, Live, at VirtualInvestorConferences.com April 4th

  4/1/2019

  Dyadic International, Inc. (the "Company") (OTCQX: DYAI), , today announced that its President and Chief Executive Officer, Mark Emalfarb will present live at VirtualInvestorConferences.com on April 4th.

• 

  From “Jeans to Genes”: Mark Emalfarb Thinks He Can Revolutionize Biopharma Manufacturing

  8/7/2018

  Mark Emalfarb, founder, chairman and chief executive officer of Jupiter, Florida-based Dyadic International, believes he knows how to revolutionize biopharma manufacturing. Emalfarb took time out to talk to BioSpace about his company and its C1 technology platform.

• Dyadic International Announces Research and Development Collaboration to Produce An Active Ingredient in C1

  2/7/2018

  The deal will explore the potential of its C1 technology to produce an important active moiety with an integrated, global biotech company.

• Dyadic International Announces Research and Development Collaboration With the Israel Institute for Biological Research (IIBR) to Combat Emerging Diseases & Threats

  1/16/2018

  IIBR is a governmental, applied research institute specializing in the fields of biology, medicinal chemistry and environmental sciences.

• Dyadic International Reports Third Quarter 2017 Financial Results

  11/10/2017

  Management will host a conference call to discuss the financial results for the quarter ended September 30, 2017.

• Dyadic International to Announce Third Quarter 2017 Financial Results and Host Conference Call on Thursday November 9, 2017

  10/27/2017

  A conference call will be held at 5:00 p.m. Eastern Time to discuss those results.

• Dyadic Announces $5 Million Stock Repurchase Program

  8/17/2017

• Dyadic Reports Second Quarter 2017 Financial Results

  8/11/2017

• Dyadic Announces The Conclusion Of Its Research Services Agreement With DuPont

  8/7/2017